Company news

Share this article:

GlaxoSmithKline and Tolerx, have announced a global collaboration deal worth up to $760 million to develop and commercialize otelixizumab (TRX4), a novel humanised anti-CD3 monoclonal antibody that has potential across a broad range of autoimmune and immune-mediated inflammatory diseases, including type 1 diabetes.

Pfizer and Taisho Pharmaceutical have signed a letter of intent for development and commercialization rights of Taisho's pre-clinical stage schizophrenia drug candidate TS-032 outside Japan.

Merck said it has been advised that the NDA for OTC Mevacor (lovastatin) will be reviewed by the FDA's Joint Meeting of the Nonprescription Drugs Advisory Committee and the Endocrinologic and Metabolic Drugs Advisory Committee on Dec. 13. Merck is seeking approval of lovastatin 20 mg taken once daily to help lower cholesterol.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.